Business development

Cancer accounts for billions every year in medical expenditures and additional costs in short-term and long-term disability, as well as the loss of productivity for both patients and caregivers.
We recognise the importance of innovation in early-stage cancer diagnostics across the health care ecosystem.

Cancer is a major public health problem worldwide with 19.3 M cases and 10 M deaths in 2020.
The number of new cases is estimated to increase to 28M, with 16M deaths per annum by 2040 .

Glycanostics is an innovative start-up company developing diagnostic tests for eleven types of cancer using magnetic beads-based ELISA to detect glycan changes. Our patented solution is based on liquid biopsy and represents a novel and unique approach.

In 2022 we plan to file CE certification for the prostate cancer diagnostic test, followed by breast cancer test in 2023.

Our pipeline includes diagnostic tests for 9 additional cancer types:

Lung cancer
Pancreatic cancer
Colorectal cancer
Stomach cancer
Liver cancer
Ovarian cancer
Testicular cancer
Bladder cancer
Thyroid cancer

Our strategy is to partner with a multi-national pharmaceutical or diagnostic company and grant an exclusive licence to commercialise our products world-wide.

Business development

Would you like to discuss potential strategic collaboration with us?

LET’S MAKE THIS REVOLUTION IN CANCER DIAGNOSTICS TOGETHER !

Glycanostics, s.r.o. currently implements an APVV project ProGlyCan funded via grant agreement number APVV-20-0476.